Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells

SIMPLE SUMMARY: The incidence rate of metastatic melanoma has been rapidly increasing worldwide and its 5-year survival rate is very low. Due to partial responses, various side effects, and resistance to any known cancer therapeutics, more potent and safer therapeutics are needed to increase the sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Min Seung, Lim, So Hyun, Yu, Ah-Ran, Hwang, Chi Yeon, Kang, Insug, Yeo, Eui-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918982/
https://www.ncbi.nlm.nih.gov/pubmed/33671902
http://dx.doi.org/10.3390/biology10020153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918982/
https://www.ncbi.nlm.nih.gov/pubmed/33671902
http://dx.doi.org/10.3390/biology10020153

Ejemplares similares